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Summary: A micromethod for the determination of acetylator phenotype using the method of Bratton & Marshall
((1939) J. Biol. Chem. 128, 537-550) was adapted to the Abbott Bichromatic Analyzer (ABA-100). Advantages of
this procedure include: (a) the requirement for small blood samples (20 ) making it a suitable pediatric method and
eliminating the need for venipunctures;(b) elimination of tedious manual reading of absorbances of samples and
mathematical manipulation of data by the automated capabilities of the ABA-100; (c) an increase in the accuracy
of the assay by reading samples at two wavelengths thereby correcting for differences in background.
Eine halbautomatische Bratton & Marshall-Mikromethode zur Bestimmung des Acetylator-Phaenotyps von Kanin-
chen mit dem Abbott Bichromatic Analyzer-100
Zusammenfassung: Eine Mikröinethode für die Bestimmung des Acetylator-Phaenotyps nach dem Prinzip von
Brätton & Marshall ((1939) J. Biol. Chem. 128, 537-550) wurde an den Abbott Bichromatic Analyzer (ABA-100)
adaptiert. Die Vorteile dieses Verfahrens umfassen: (a) geringes Probenvolumen (20 Blut), weshalb die Methode
für die Kinderheilkunde geeignet ist und Venenpunktion entfällt ;(b) Wegfall des ermüdenden Ablesens der Absorp-
tionen der Proben und Datenverarbeitung durch die automatisierten Möglichkeiten des ABA-100; (c) eine Verbesse-
rung der Analysengenaüigkeit durch Untergrundkorrektur infolge Messung bei zwei Wellenlängen.
Introduction
The N-acetylation of chemical agents with an aromatic
amine character such as isoniazid, hydralazine, phenelzine,
procainamide, nitrazepam, and sulfanilamide derivatives
have been shown to exhibit a genetically controlled
polymorphism in both animals and humans (1,2). This
polymorphism in acetylation rate can alter the thera-
peutic efficacy and toxicity of these and other chemical
agents biotransforined by this metabolic pathway. For
the purpose of treating individuals more effectively,
evaluating toxicological data more thorougjtily and
routinely phenotyping individuals in population genetic
studies, a simple and rapid method of determining the
acetylating ability of laboratory animals and/or humans
using small blood samples would be desirable and useful.
In the course of our studies on the toxicity of isoniazid
it became necessary to routinely determine the acetylator
phenotype of rabbits. The method of Bratton & Marshall
(3) using sulfadiazine as a substrate for the acetylating
enzyme, was scaled down to a micromethod and semi-
automated by utilizing the Abbott Bichromatic Analyzer's
(ABA-100) capability to automatically read samples at two
wavelengths and convert the differences in absorbance
( ) to ^g sulfadiazine per milliliter of blood.
Materials and Methods
Apparatus
An Abbott Bichromatic Analyzer-100 (ABA-100, Abbott Scienti-
fic Products Division, South Pasadena, California, 91030) and a
Cary-15 recording spectrophotometer equipped with a high-
intensity light source (Applied Physics Corp., Monrovia, Cali-
fornia, 91016) were used for all absorbance measurements.
Reagents
Sulfadiazine, sodium nitrite, N-1-naphthylethylenediamine dihy-
drochloride, trichloroacetic acid and ammonium sulfamate
were purchased from local suppliers. The sodium salt of sul-
fadiazine was prepared by mixing equimolar concentrations of
an ethanolic solution containing 80 g/1 sodium hydroxide with
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an ethanolic solution of sulfadiazine. The resulting salt was
washed with ethyl alcohol and dried under vaccum. An
aqueous stock solution of sodium sulfadiazine equivalent to
200 mg of sulfadiazine per liter was used for the preparation of
working standards. The dosing solution, an aqueous solution
of sodium sulfadiazine equivalent to 200 g/1 sulfadiazine, was
administered at 0.1 ml/kg (20 mg/kg) over a 60 s time period in
the marginal ear vein of male New Zealand White rabbits
(1.8-3.5 kg) deprived of food for 16-18 h.
Procedure
Blood (20 μΐ) was collected with micropipettes (Microcaps,
Drummond Scientific Co., Acadian Instruments Ltd., Etobi-
coke, Ontario M9C 4V3) from the opposite ear vein at 20,40,
60,120, and 180 min after dosing with sulfadiazine and
immediately transferred to 10 X 75 mm culture tubes
containing 0.94 ml of water. Following complete hemolysis,
proteins were precipitated with 0.24 ml of trichloroacetic acid
(150 g/1) and the supernatants separated by centrifugation.
Aliquots (0.5 ml) of blanks, standards and sample supernatants
were transferred to clean 10 X 75 mm culture tubes for the
assay of free sulfadiazine. Reagent solutions were added to
culture tubes using re/micropipettors (microre/pettor, Scientific
Manufacturing Industries, Emeryville, California 94608). 50 μΐ
of freshly prepared aqueous sodium nitrite (1 g/1) was added,
mixed, and the solution allowed to stand for 3 min followed
by 50 μΐ of ammonium sulfamate (5 g/1). After mixing again
and allowing the mixture to stand for 2 min, 50 μΐ of an aqueous
solution of N-1-naphthylethylenediamine dihydrochloride (1 g/1)
was added. The contents were mixed, transferred to an ABA-
100 multicuvette and the color developed for 5 min then
assayed with the ABA-100. The operating conditions for the
ABA-100 were as outlined in table 1. For comparisons on the
Cary-15 the assay was scaled-up by five-fold.
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For routine assays of blood for sulfadiazine the most convenient
working standards were 1.667,0.833 and 0.333 mg/1 prepared
respectively from 1.00,0.50 and 0.20 ml of stock sulfadiazine
solution, 24 ml of trichloroacetic acid (150 g/1) and sufficient
water to give a final volume of 120 ml. Blanks were similarly
prepared with the exception that stock sulfadiazine was
replaced with distilled water. When 0.50 ml of the sulfadiazine
working standards were assayed as described above they repre-
sented 100, 50 and 20 mg/1 of blood, respectively.
Data for the sulfadiazine standard curve and the sulfadiazine
elimination curves from the blood were fitted by regression
analysis using a Nova 800 minicomputer. Results obtained
from the ABA-100 and the Cary-15 were compared using the
unpaired Student Mest. Variance of the absorption coefficients
were analyzed by an F-test.
Results and Discussion
A scan of diazotized sulfadiazine between 450 nm and
650 nm showed a maximum absorption peak at 543 nm
returning to the baseline at 650 nm (fig. 1). On the basis
of this observation the 550/650 filter supplied with the
ABA-100 was chosen for the assay of sulfadiazine. Stan-
dards equivalent to between 10 and 500 rrig of sulfadiazine
per liter of blood were prepared in water and diazotized.
The bsorbance at 550 nm and the difference in absorb-
ance (ΔΑ) at 550/650 nm were determined on the Cary-








Fig. 1. Representative scan of diazotized sulfadiazine. Sulfa-
diazine (3.85 mg/1 final concentration) was diazotized
as indicated in the materials and methods and scanned
with a Cary-15 recording spectrophotometer between
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Fig. 2. Linearity of the standard curves assayed by a) the con-
ventional method (Cary-15, λ = 550 nm) and b) the
described method (ABA-l 00, .filter 550/650). .
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curves with their slopes, Y-intercepts and correlation
coefficients were calculated (tab. 2). A statistical differ-
ence in the slopes and the Y-intercepts of the two stan-
dard curves could not be demonstrated. A slightly
higher correlation coefficient was observed between the
standard curve and the actual absorbance readings when
the ABA-100 was employed, suggesting that the variance
about the standard curve was less when the assay was per-
formed with the ABA-100. Examination of the molar
absorption coefficients (e) calculated from data obtained
with the two instruments indicated that the e values were
not significantly different, however the variance of e was
found to be statistically smaller (F-test) with the ABA-
100 (tab. 2). The higher correlation coefficient and
the smaller variance observed with the ABA-100 was
probably the result of (a) the elimination of the human
error associated with the manual estimation of absorb-
ances with the Cary-15 and (b) the bichromatic features
of the ABA-100.
The coefficient of variation (CV) for the determination
of sulfadiazine in blood using the ABA-100 is presented
in table 3. The overall CV was found to be 2.78% indi-
cating this method to be a precise and reliable method
for the determination of sulfadiazine in blood.
Using the ABA-100 method, sulfadiazine elimination pro-
files from the blood of male New Zealand White rabbits
were examined. Typical elimination profiles from slow,
medium and fast acetylator rabbits with the corre-






























11.52 X 106 3.45 Χ 106 0.002
6.68 3.62
a Variance of e analyzed by F-test. All other comparisons were
made using the unpaired Student Mest.
Tab. 3. Estimation of the precision of the ABA-100 method for























sponding halflife, correlation coefficient and the elimin-
ation rate constant (k) and its standard error are presented
in figure 3. The frequency distribution of sulfadiazine half-
life in 137 rabbits is illustrated (fig. 4). Two groups of
animals were differentiated by a half-life antimode at 60
to 70 min confiimingFrymoyer&Jacox's (4) earlier
finding.
The intravenous route of administration of sulfadiazine
was used in both this study and that ofFrymoyer &
Jacox (4) and would be preferable for all phenotyping
studies since the effect of absorption upon the apparent








20 40 60 80 100 120 140
t i m i n ]
160 180 200
Fig. 3. Typical sulfadiazine elimination profiles from the blood
of a
slow (o, k = 0.00514 ± 0.0036 min·1; r = 0.9927;
11/2 = 135 min),
medium (A, k = 0.00943 ± 0.00038 min'1; r = 0.9975;
11/2 = 74 min) and
fast (·, k = 0.01805 ± 0.00293 min"1;! = 0.9870;
tj/2 = 38 min)
acetylator male New Zealand White rabbit following the
intravenous administration of sulfadiazine (20 mg/kg).
The elimination rate constant (k) and its standard error,
the half-life of free sulfadiazine ti/2 and the correlation
coefficient (r) for each of the animals were computed
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Fig. 4. Frequency distribution of sulfadiazine halflife in
137 male New Zealand White rabbits assessed by the
described ABA-100 method.
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ever, intravenous administration of sulfadiazine or in
fact any chemical agent to humans is associated with an
additional patient-risk (hepatitis) and technological
difficulties (the skills of a doctor or qualified nurse to
make the actual intravenous injection). Recently Weber
& Brenner (5) and Hoo et αϊ (6) have published methods
for the determination of acetylator phenotype in humans
following oral administration of sulfamethazine, a
dimethyl analogue of sulfadiazine. Since sulfadiazine
and sulfamethazine are rapidly absorbed at similar rates
from the gastrointestinal tract (7), it would appear
that when circumstances dictate the oral route of sul-
fadiazine administration could be used to assess the
acetylator phenotype of individuals. If the oral route of
sulfadiazine administration is to be used to phenotype
humans then the blood collection times must be ad-
justed so that they fall on the elimination phase of the
blood profile curve. According to Olson etal(8), with
a 10 mg/kg dose of sulfamethazine the absorption phase
was complete by 3 hours. To prevent extended waiting
periods for ambulatory patients and facilitate the pheno^
typing procedure, the number of blood collections
could be reduced to two samples, perhaps a 3 and 4 hour
sample. Since only 20 μΐ blood samples are required for
the assay, blood could be collected from finger or heel
punctures avoiding the difficulties associated with
venipunctures and making this a microsemi-au torn ate d
method suitable for large scale population genetic studies.
The modified Bratton & Marshall method described above
offers a number of advantages over existing methods:
(a) The requirement for small blood samples (20 μΐ)
makes this a suitable pediatric method whereby
sufficient blood can be obtained from a finger or
heel puncture.
(b) The capabilities of the ABA-100 to automatically
read absorbances and express results in terms of
mg of sulfadiazine per liter of blood reduces the
assay time considerably and circumvents tedious
manual calculations.
(c) Absorbance differences in the baseline due to tur-
bidity or cloudiness are corrected by the fact that
samples are examined at two wavelengths (550/
650 nm) with the ABA-100 and the assay based
on the differences between these two absorbance
reading.
(d) By using the pharmacokinetic approach instead of
a single blood sample, phenotype misclassification,
a real possibility (9), is minimized.
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